Analysis of a cDNA clone derived from retrovirus-transformed rat fibroblasts has recently suggested that the mature 50-amino-acid form of transforming growth factor a (TGFa) is derived from a 159-amino-acid transmembrane precursor by proteolytic cleavage. To understand the processing of the 
Transforming growth factor a (TGFa) is a small polypeptide, of approximately 50 amino acids, which appears to be structurally and functionally related to epidermal growth factor (EGF) (15, 16) . These polypeptides show significant sequence homology and appear to have evolved by gene duplication from a common ancestral molecule (15) . TGFa and EGF compete for binding to the same cell surface receptor, the EGF receptor, and activate the associated tyrosine kinase activity of the receptor molecule (17, 18) . Although these growth factors are potent mitogens in tissue culture, recent reports have suggested that TGFa may have different biological properties from those of EGF. TGFa has been reported to be more potent at promoting calcium release from rat fetal long bones (6, 7) and as an angiogenesis factor (20) .
TGFa, initially identified in the medium of retrovirustransformed rodent cells (1, 26, 27 ; for reviews, see reference 24 and D. R. Twardzik and J. R. Ranchalis, UCLA Symp. Bone Cartilage, in press), is expressed in a variety of human tumors and tumor cell cultures (16, 23) and is thought to play a role in the malignancy process. Analysis of the cloned TGFa cDNA has revealed some interesting features regarding its expression. As is true of several other growth factors, TGFa appears to be processed from a larger precursor molecule. In the rat and the human, the precursors are 159 and 160 amino acids, respectively, and each contains a typical leader sequence and an extremely hydrophobic domain resembling a transmembrane region (2, 11) . This led to the prediction that the mature 50-amino-acid form of TGFa is derived by proteolytic release from a membrane-bound precursor molecule. Of particular interest is the finding that proteolysis occurs at unique Ala-Val-Val sequences and is most probably mediated by a protease having elastase-type specificity (11; D. C. Lee press). The fact that an unusual protease is involved in the processing of the precursor raises the possibility that proteolysis is a regulatory event in the generation of the mature growth factor. Moreover, the marked sequence conservation of the entire precursor that is evident in a comparison of the human and rat cDNAs may suggest that the precursor has functions distinct from those of the mature growth factor.
To understand the structure and processing of the TGFa precursor in more detail, we fibroblasts to release a mature Mr 6,000 TGFa form into the culture medium.
MATERIALS AND METHODS
Cell culture and radioactive labeling. Fisher rat embryo fibroblast (FRE) cells and their Snyder-Theilen feline sarcoma virus-transformed counterparts were from previously described clones (27) . Leydig testicular tumor cells were generously provided by Greg Mundy. BHK fibroblasts were provided by Richard Palmiter. Leydig tumor cells were grown in RPMI 1640 supplemented with 15% fetal bovine serum. All other cells were grown in Dulbecco modified Eagle medium containing 10% fetal bovine serum.
Confluent cultures of cells were labeled with [35S]cysteine (>1,000 Ci/mmol; New England Nuclear Corp.) in cysteinefree Dulbecco modified Eagle medium containing 5% dialyzed fetal bovine serum. FRE, ST-FeSV-transformed FRE, and Leydig tumor cells were labeled at 500 uCi/ml. For experiments involving BHK cells or the 5:2 transfectants, cells were induced with 2 ,uM cadmium sulfate and 100 ,uM zinc chloride prior to being labeled. Following a 6-to 10-h induction period, cells received cysteine-free DME supplemented with 5% dialyzed fetal bovine serum, 200 ,uCi of [35S]cysteine per ml, and an equivalent amount of metal ion inducer.
Construction of the metaflothionein-rat TGFa plasmid. The TGFa expression vector, was constructed by using plasmid EV142 (13) , which contains the mouse metallothionein 1 promoter fused to the 3' untranslated region of the human growth hormone gene (kindly provided by Richard Palmiter). The mouse metallothionein 1 sequence is contained in an 800-base-pair (bp) fragment which extends from the 5' flanking sequence through the promoter and includes the first 64 bp of exon 1. This fragment is fused by a unique BglII site to a 625-bp human growth hormone fragment which contains the 3' untranslated region of exon 5, the polyadenylation signal, and 3' flanking sequences. These fragments are contained in pBX322, a high-copy-number derivative of pBR322 which contains an XhoI linker at about position 3000. To generate pEV2, a 700-bp SmaI fragment which includes the entire rat TGFa coding region was inserted into the unique BglII site. Clones with the proper orientation were selected, and DNA was isolated for transfection.
Transfection of BHK cells. Subconfluent BHK cells grown in 100-mm dishes containing 10 ml of complete medium (Dulbecco modified Eagle medium with 10% fetal bovine serum) were transfected with 20 ,ug of pEV2 as a calcium phosphate precipitate (28) in the presence of 1 mM chloroquine. After the cells had been incubated for 5 h at 37°C, the medium was removed and replaced with 10 ml of fresh medium. After an additional 24 h in culture, Geneticin (G418; GIBCO Laboratories) was added to the medium at 500 ,ug/ml. Antibiotic-resistant clones were visible after 1 week; these clones were isolated and tested for their expres- Northern blots were performed essentially as described previously (10) with poly(A)+ RNA selected by chromatography on oligo(dT)-cellulose.
Production of antipeptide antibodies. Peptides were synthesized by solid-phase techniques on a Beckman automated instrument (4) and purified by preparative high-pressure liquid chromatography. The composition of the peptides was confirmed by amino acid analysis. Purified peptides were coupled to bovine -y-globulin through the cysteine residue and used to immunize New Zealand White rabbits (3) . Immunization schedules were as described previously (3) .
Immunoprecipitation analysis. Radiolabeled cell cultures were lysed in detergent-containing buffer (20 mM Tris hydrochloride [pH 7.4], 150 mM NaCl, 0.5% sodium deoxycholate, 1.0% Nonidet P-40, 1 mM EDTA, 2 mM phenylmethysulfonyl fluoride, 200 kallikrein inhibitory units of aprotinin [Sigma Chemical Co.] per ml) and clarified by centrifugation at 100,000 x g for 30 min at 4°C. A 100-pul portion of lysate equivalent to 5 x 105 to 1 x 106 cells was precleared with 10 mg of Staphylococcus aureus and then incubated with 5 ,ul of serum at 0°C for 1 h. Immunocomplexes were collected on S. aureus and washed as described previously (3) . Peptide-blocking experiments were performed with purified peptide. Immunoprecipitated samples were lysed with sodium dodecyl sulfate (SDS)-containing buffer and electrophoresed on 15% polyacrylamide or 12 to 20% gradient polyacrylamide gels (9) . Radiolabeled proteins were detected by fluorography with En3Hance (New England Nuclear).
Radioreceptor assay. The binding of 125I-labeled EGF to its receptor was measured on monolayers of Formalin-fixed A431 cells as previously described (1) . Concentrations of TGFa are expressed as nanogram equivalents of EGF, i.e., the amount required to produce an inhibition of 1251I-labeled EGF binding equivalent to that produced by a known amount of EGF.
Membrane fractionation. Radiolabeled cell cultures were collected by scraping. Cells were swollen in hypotonic lysis buffer (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 6.9], 1 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 200 kallikrein inhibitory units of aprotin per ml) at 2 x 107 cells per ml for 20 min at 4°C and Dounce homogenized. Nuclei and unbroken cells were removed by centrifugation at 2,000 x g for 15 min at 40C, and the supernatant was further fractionated into pelleting (P100) and supernatant (S100) fractions by centrifugation at 100,000
x g. The P100 fraction was separated on discontinuous sucrose gradients essentially as described previously (14) . For immunoprecipitation analysis, samples were adjusted to 1 x in detergent lysis buffer. RESULTS Expression of rat TGFoa in BHK cells. To characterize the TGFa precursor, we prepared an expression vector (pEV2; Fig. 1A ) that places the rat TGFa cDNA under the control of the inducible mouse metallothionein I promoter. Induced transcription of this vector would yield a hybrid mRNA of 1 kilobase pair (kb) containing 700 base pairs (bp) of TGFa cDNA, 64 bp of metallothionein gene, and 240 bp of the human growth hormone segment. The last of these was present to provide a 3' noncoding sequence and polyadenylation signal. pEV2 was cotransfected into BHK cells along with the selectable neomycin resistance marker, and cells resistant to G418 were isolated. Expression of TGFa mRNA in transfected BHK cells was determined by solution hybridization as described previously (10) . One transfectant (termed 5:2) was shown to express the hybrid TGFa mRNA at high levels following induction with cadmium and zinc and was used for further characterization. Immunoprecipitation of the TGFa precursor polypeptide with site-specific antipeptide antibodies. Site-specific antibodies directed toward peptide sequences within the predicted rat TGFa precursor protein molecule (11) were generated in rabbits by using synthetic peptides as immunogens. Figure  2A shows the peptide sequences which were used, as well as their relative locations within the TGFa precursor polypeptide. The TGFa antibodies were directed toward epitopes present within the carboxy-terminal region of the precursor molecule and are precursor specific.
Antisera were tested for their ability to specifically immunoprecipitate induced proteins from [35S] known to produce high levels of mature, fully processed TGFa were used for comparison. Figure 4A shows the results obtained. ST-FeSV-transformed FRE cells produced by far the greatest amount of EGF-competing activity into --culture supernatants, approaching nearly 6 ng equivalents of EGF-competing activity per ml of conditioned culture medium. Induced 5:2 cells also contained competing activity, albeit at lower levels (ca. 0.8 ng equivalents per ml of -v-conditioned medium). Supernatants from uninduced 5:2 cells and the parental BHK cell line treated with cadmium and zinc produced nondetectable levels of EGF-competing activity.
To examine the nature of the TGFa molecule secreted by the induced 5:2 cells, conditioned medium was fractionated over a high-pressure liquid chromatography gel permeation column and fractions were assayed for EGF-competing activity (Fig. 4B) . The EGF-competing activity induced from 5:2 cells was detected as a Mr 6,000 protein species which appeared to coelute with the fully processed TGFa form found in the supernatant of ST-FeSV-transformed FRE cells. No species to one of Mr 13,000 to 17,000. After a 160-min chase, the detected TGFa precursor species comigrated with the precursor immunoprecipitated from induced 5:2 cells labeled for 8 h (control lane), suggesting that complete processing had occurred over this 160-min chase period. The half-life of the precursor identified with anti-TGFa137.159 was approximately 2 h. We cannot rule out the possibility that this apparent half-life is due to an early cleavage event involving the carboxy-terminal epitopes used for immunoidentification.
The TGFa precursor protein is membrane associated. The membrane localization of the TGFa precursor was determined by cell fractionation and differential centrifugation. 6A. Nearly all the immunoreactive TGFa precursor protein was found in the P100 fraction (P100; lanes 5:2i), suggesting a membrane association. To delineate this potential membrane association further, the P100 fraction was separated by discontinuous sucrose gradient centrifugation. In this analysis, the plasma membrane fraction collects at the 20/35% sucrose interphase, since it possesses the lowest density of the microsomal components. Results of the immunoprecipitation analysis of the gradient fractions are shown in Fig.  6B . Densitometric analysis of the autoradiograph reveals that 52% of the Mr 13,000 to 17,000 immunoreactive TGFa precursor fractionates within the 20/35% sucrose interphase. Marker enzyme analysis shows that 64% of the membraneassociated 5'-nucleotidase activity (29) is located within this sucrose fraction (data not shown). These results suggest colocalization of the TGFa precursor with the plasmalemma fraction.
DISCUSSION
In this study, we expressed a transfected cDNA encoding the complete rat TGFa precursor in nontransformed BHK fibroblasts to study the expression and processing of the TGFa molecule. The expressed TGFa precursor protein was identified and characterized by site-specific immunological reagents directed toward peptide epitopes within the carboxy end of the precursor polypeptide. A summary of our results follows. First, the TGFa precursor was readily identified in the transfectant BHK fibroblasts. The most stable from of this protein behaved on SDS-polyacrylamide gels as a diffusely migrating protein with apparent Mr 13,000 to 17,000. This value is consistent with the predicted molecular weight of the precursor molecule. Second, immunoreactive proteins which appear to comigrate with the TGFa precursor detected in the BHK transfectant were found in two cell lines, Leydig testicular tumor and ST-FeSVtransformed FRE cells, known to produce TGFa naturally, but were not found in nontransformed FRE or BHK cells. Third, the Mr 13,000 to 17,000 precursor molecule expressed in the transfectant BHK cells colocalized with the plasmalemma of fractionated cells; this result is consistent with a proposed membrane localization of the precursor molecule based on an analysis of the TGFa cDNA (11) . Finally, these nontransformed BHK fibroblasts were demonstrated to be capable of proteolytically processing the TGFa precursor molecule to the mature Mr 6,000 species.
Pulse-chase experiments allowed us to examine the processing of the TGFa precursor molecule in intact BHK transfectants and to identify processing intermediates. Our results demonstrate that the Mr 13,000 to 17,000 TGFa precursor arises from two short-lived intermediates of Mr 14,000 to 18,000 and Mr 15,000 to 19,000. The Mr 14,000 to 18,000 polypeptide is the initial translation product observed after a short pulse-label and is rapidly converted into the larger, Mr 15,000 to 19,000, intermediate. This initial processing event, which results in the apparent increase in molecular weight observed on SDS-polyacrylamide gels, may be the result of covalent posttranslational modification such as phosphorylation, lipidation, or carbohydrate addition. A typical N-linked glycosylation site is present in the predicted sequence of the TGFa precursor (11 (anti-TGFa15-159) were also able to identify similar processing intermediates (data not shown). Thus, this early stage of proteolytic processing must occur at the amino end of the precursor molecule. A loss in molecular weight of 2,000 would be consistent with cleavage of the 23-amino-acid hydrophobic leader peptide predicted from the sequence of TGFa cDNA (13) .
Complete processing of the Mr 13,000 to 17,000 TGFa precursor polypeptide into the released Mr 6,000 form of TGFa was evident in the supernatants of the transfected BHK fibroblasts. Media conditioned by these cells contained TGFa activity (as measured by EGF competition) which, upon gel permeation chromatography, cofractionated with the fully processed 50-amino-acid TGFa form. Proteolytic cleavage of TGFa from its precursor occurs at Ala-Val-Val sequences and is most probably mediated by a protease having elastase-type specificity (2, 11) . The ability of nontransformed BHK fibroblasts to completely process the TGFa precursor indicates that these cells do express this protease and suggests that processing is not mediated by a tumor-specific proteolytic enzyme. It is entirely possible, however, that the levels of this protease are elevated in the malignant state. In this regard, it is interesting that while ST-FeSV-transformed FRE cells secrete significantly higher levels of the mature growth factor, they contain significantly lower levels of the Mr 13,000 to 17,000 species. This is also true of the Leydig tumor cells (data not shown), suggesting that the half-life of the precursor is considerably shorter in malignant cells than in nontransformed BHK cells.
Several size classes of TGFa have previously been observed in the supernatants and extracts from tumor cells (1, 27) . Although the Mr 6,000 form of TGFa has been well characterized (15) , its relationship with the larger forms of TGFa precursor is not well documented. Linsley et al. (12) and Ignotz et al. (8) used antipeptide sera directed toward the carboxy terminus of the 50-amino-acid TGFa molecule to characterize the larger secreted forms. Several molecular weight classes of immunoreactive material were identified, the most conspicuous of which was a polypeptide of molecular weight approximately 20,000 (8, 12) . Ignotz et al. extended this analysis further and revealed that after digestion with elastase, this larger precursor form of TGFa released an Mr 6,000 polypeptide with properties of mature TGFa (8) . The relationship of this Mr 20,000 secreted (released) form with the precursor forms detected in this report remains to be established. Our present results indicate that nontransformed BHK fibroblasts release only the mature, fully processed 50-amino-acid TGFa. This raises the possibility that tumor cells process the TGFa precursor differently from nontransformed cells, resulting in the release of larger TGFa precursor forms. The precursorspecific antibodies described here should prove useful in assessing the relationship of these larger secreted forms with the TGFa precursor, as well as in characterizing the highmolecular-weight forms of TGFa-like species previously found in the urine of patients with disseminated cancer (21, 25) .
Although much is known concerning the biological properties of TGFa, the role of this growth factor in the development of the malignant state remains unclear. The production of TGFa by a variety of transformed cells (24; Twardzik and Ranchalis, in press), as well as its occurrence in the
